Gregory J Bever1, Dan J Kim1, Armin R Afshar1, James L Rubenstein2, Bertil E Damato1. 1. Ocular Oncology Service, Department of Ophthalmology, University of California San Francisco, San Francisco, California; and. 2. Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Abstract
PURPOSE: To report the outcome of a previously vitrectomized eye having less lymphoma disease burden compared with the contralateral nonvitrectomized eye over the course of 3.5 years while on systemic chemotherapy. METHODS: Case report. RESULTS: A 51-year-old man with vitreoretinal lymphoma with central nervous system involvement underwent vitrectomy in his left eye. Over the following 3.5 years on systemic chemotherapy, the left eye had less lymphoma disease burden compared with the contralateral nonvitrectomized right eye. CONCLUSION: Therapeutic vitrectomy may be a useful adjunct to systemic chemotherapy in vitreoretinal lymphoma, particularly in cases of vitreous predominant disease manifestation.
PURPOSE: To report the outcome of a previously vitrectomized eye having less lymphoma disease burden compared with the contralateral nonvitrectomized eye over the course of 3.5 years while on systemic chemotherapy. METHODS: Case report. RESULTS: A 51-year-old man with vitreoretinal lymphoma with central nervous system involvement underwent vitrectomy in his left eye. Over the following 3.5 years on systemic chemotherapy, the left eye had less lymphoma disease burden compared with the contralateral nonvitrectomized right eye. CONCLUSION: Therapeutic vitrectomy may be a useful adjunct to systemic chemotherapy in vitreoretinal lymphoma, particularly in cases of vitreous predominant disease manifestation.
Authors: Mandeep S Sagoo; Hemal Mehta; Andrew J Swampillai; Victoria M L Cohen; Sepideh Z Amin; P Nicholas Plowman; Sue Lightman Journal: Surv Ophthalmol Date: 2013-12-31 Impact factor: 6.048